CA
NZ
UK
AU
IND
US
CVRx, Inc. (NASDAQ: CVRX) announced Thursday that Chief Revenue Officer Robert John’s employment terminated on Aug 10, and longtime executive Paul Verrastro assumed the role of interim head of sales. The company said the transition was immediate, with Verrastro bringing more than three decades …
Imunon, Inc. reported a net loss of $2.8 million for Q2 2026, resulting in an EPS of $-0.54, surpassing the $-0.94 consensus estimate. This performance highlights challenges amid a significant 60% year-to-date drop in share price, suggesting investor caution moving forward.Key HighlightsEPS of $-0.54 …
Keenova Therapeutics reported $517 million in net sales for Q2 2026, reflecting a $253 million increase year-over-year. The raised growth outlook for Acthar Gel to 20-22% signals strongDemandfor its leading therapeutics, making it a compelling opportunity for investors.Key HighlightsActhar Gel net sales grew to …
Medtronic (NYSE: MDT) reported Q4 revenue of $9.8 billion, up 9.9% year-over-year, with EPS at $1.55, missing the consensus estimate of $1.56. The company's revenue growth was driven by its Cardiac Ablation Solutions, which saw a 78% increase in revenue globally, and a 124% …
Neurogene Inc. secured $144 million in funding, extending its cash runway into the first quarter of 2029, while reporting significant developmental milestones for its NGN-401 program in Rett syndrome, affirming its position as a growing player in gene therapy. Investors should watch for topline …
Shattuck Labs reported a second quarter EPS of $-0.12, somewhat better than the consensus estimate of $-0.14, reflecting improved clinical progress. The company's solid cash position of $208.3 million extends its operational runway into 2029, providing assurance for investors.Key HighlightsShattuck's cash and equivalents stand …
Aura Biosciences, Inc. plans to reduce its workforce by approximately 20%, incurring estimated costs of $2.9 million to $3.2 million. This restructuring aims to extend its cash runway into early 2029, signaling a strong focus on its ocular oncology pipeline for investors.Key HighlightsThe workforce …
Leadership Transition and Its Timing
C4 Therapeutics narrowed its Q2 net loss to $23.6 million, down from $26.0 million a year earlier. This reduction indicates improved cost management, which may enhance investor confidence as the company advances pivotal cemsidomide trials through 2027.Key HighlightsC4 Therapeutics continues to prioritize the development …
Harvard Bioscience reported anEarnings Per Share(EPS) of $-0.14, surpassing analyst expectations by 33% against a $-0.21 consensus estimate. This performance indicates strengthening fundamentals in a challenging market, potentially appealing to investors looking for growth opportunities.Key HighlightsHarvard Bioscience (NASDAQ: HBIO) reported an earnings per share …
Please wait processing your request...